癌症患者静脉血栓栓塞症的治疗：临床试验有哪些新消息？
Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?
机构信息
Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy.
Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy.
出版信息
Thromb Res. 2018 Apr;164 Suppl 1:S168-S171. doi: 10.1016/j.thromres.2018.01.031.
About 15% of patients with cancer experience one or more episodes of venous thromboembolism (VTE) during the course of their disease. In patients with cancer, VTE has a substantial impact on the quality of life and care. Current guidelines recommend low-molecular-weight heparin (LMWH) as first choice therapy for long-term anticoagulation in cancer patients with VTE. However, there are several practical issues concerning the long-term use of these anticoagulants. In the last years, several direct oral anticoagulants (DOACs) have emerged as alternatives to heparins and vitamin K antagonists for the treatment of VTE, but data regarding both efficacy and safety of DOACs in the subgroup of patients with cancer treatments were limited. The results of two studies evaluating the clinical benefit of treatment of VTE with direct oral anticoagulants in patients with cancer have been recently presented. Several studies comparing DOACs with LMWH are currently ongoing.
约 15%的癌症患者在疾病过程中会经历一次或多次静脉血栓栓塞症（VTE）。在癌症患者中，VTE 对生活质量和护理有重大影响。目前的指南建议低分子肝素（LMWH）作为癌症合并 VTE 患者长期抗凝的首选治疗方法。然而，这些抗凝剂的长期使用存在一些实际问题。在过去几年中，几种直接口服抗凝剂（DOACs）已作为肝素和维生素 K 拮抗剂的替代品出现，用于 VTE 的治疗，但关于 DOACs 在癌症治疗患者亚组中的疗效和安全性的数据有限。最近报告了两项评估直接口服抗凝剂治疗癌症患者 VTE 的临床获益的研究结果。目前正在进行多项比较 DOACs 与 LMWH 的研究。
Zotero 插件